US FDA takes step to change peptide compounding policy

Overview of the Regulatory Action

Reuters has reported that the U.S. Food and Drug Administration is moving to revise its policy governing the compounding of peptide drugs, a category of therapeutics that has exploded in popularity and regulatory scrutiny over the past several years. The wire report, circulated via Google News, is brief and does not detail the specific mechanism FDA is using — whether a draft guidance document, a Federal Register notice, an update to the agency's bulk drug substances lists, or an enforcement policy shift. Given the limited detail available in the underlying wire item, this analysis situates the reported action within the broader statutory and regulatory framework FDA has used to police peptide compounding, and flags the specific questions that will need to be resolved once the agency publishes fuller documentation.

What is clear is that peptides — including GLP-1 receptor agonists such as semaglutide and tirzepatide, as well as so-called "research peptides" like BPC-157, thymosin beta-4, and epitalon — have become the single most contentious category in compounding policy since the 2012 New England Compounding Center (NECC) fungal meningitis outbreak. Any formal step by FDA to change how these substances are treated under the compounding statutes would have immediate and material consequences for compounding pharmacies, outsourcing facilities, telehealth prescribers, and patients who have come to rely on compounded peptide products, often at lower cost than FDA-approved brand-name equivalents.

Legal Framework and Authority

FDA's authority over compounded drugs flows primarily from the Drug Quality and Security Act of 2013 (DQSA), which added Sections 503A and 503B to the Federal Food, Drug, and Cosmetic Act (FDCA). Section 503A governs traditional compounding pharmacies that prepare patient-specific prescriptions and are regulated largely at the state level, with limited FDA oversight. Section 503B created a new category of "outsourcing facilities" that may compound without patient-specific prescriptions, provided they register with FDA, comply with current good manufacturing practice (cGMP) requirements, and submit to FDA inspection.

Critically, both pathways restrict compounders to using bulk drug substances that either (1) are components of an FDA-approved drug, (2) appear in the United States Pharmacopeia (USP) or National Formulary, or (3) are included on FDA's 503A or 503B Bulk Drug Substances Lists. FDA maintains these lists through a nomination and review process involving its Pharmacy Compounding Advisory Committee (PCAC), which evaluates safety data, physicochemical characteristics, historical use, and the availability of FDA-approved alternatives. Many peptides — including several BPC-157 variants and other "research" compounds — have been nominated for these lists and have faced preliminary negative recommendations from FDA staff and the PCAC, largely due to insufficient safety and stability data, immunogenicity concerns, and the absence of a legitimate medical use history.

A second, parallel legal mechanism is Section 506E of the FDCA, which permits compounding of drugs in shortage. This provision became central to the peptide debate when semaglutide and tirzepatide were both listed on FDA's drug shortage database in 2022–2023, enabling widespread compounding by 503A and 503B entities. FDA's subsequent determinations that these shortages had resolved — first for tirzepatide in late 2024, then for semaglutide in early 2025 — triggered litigation from the Outsourcing Facilities Association and a wind-down period for compounders, with FDA stating it would exercise enforcement discretion for a limited transition window before expecting compounders to cease production of copies of commercially available GLP-1 products.

Industry Implications

Any policy shift reported by Reuters likely intersects with one or both of these legal tracks. If FDA is narrowing the bulk substances eligible for compounding, pharmacies and outsourcing facilities that have built significant revenue streams around peptides such as BPC-157, NAD+, melanotan II, or GLP-1 analogs could face compliance deadlines requiring reformulation or discontinuation. Conversely, if the step represents a clarification or formalization of criteria — rather than an outright prohibition — the industry may gain more predictability after years of ad hoc enforcement letters and shifting shortage determinations.

The outsourcing facility sector, represented by trade groups such as the Outsourcing Facilities Association and the Alliance for Pharmacy Compounding, has consistently argued that compounded peptides fill legitimate gaps in patient access, particularly for dosage forms, strengths, or combinations not commercially available. Manufacturers of FDA-approved peptide therapeutics, including Novo Nordisk and Eli Lilly, have taken the opposite position, arguing that compounding — especially of GLP-1 drugs using unapproved salt forms like semaglutide sodium or semaglutide acetate — poses safety risks and undermines the approved-drug pathway's integrity. FDA has previously issued warning letters asserting that such salt forms do not meet the statutory definition of the "same" active ingredient as the approved product, a position that remains legally contested.

Compliance Considerations

Compounders should anticipate that any FDA policy change in this space will likely include transition or enforcement-discretion periods, consistent with the agency's approach to the GLP-1 shortage wind-down. Key compliance questions pharmacies and outsourcing facilities should monitor include: whether specific peptides are being added to or removed from the 503A/503B bulk substances lists; whether FDA is tightening its interpretation of "clinical need" under 21 C.F.R. § 216.23 for 503A compounders; and whether new cGMP expectations or testing requirements (e.g., endotoxin, sterility, or impurity profiling specific to peptide synthesis) are being imposed on 503B facilities. State boards of pharmacy, which license 503A pharmacies, will also need to align their enforcement posture with any federal guidance to avoid regulatory gaps.

Looking Ahead

Because the source reporting is limited to a headline-level wire notice, the precise contours, effective dates, and legal mechanism of this policy change remain to be confirmed through FDA's official channels — likely a Federal Register notice, updated guidance document, or PCAC meeting record. Stakeholders should watch for FDA announcements in the Federal Register, updates to the 503A and 503B Bulk Drug Substances Lists on FDA's website, and any accompanying statements from the Center for Drug Evaluation and Research (CDER). Given the pattern of litigation that followed the semaglutide and tirzepatide shortage determinations, a contested rulemaking or guidance process — potentially including industry comment periods and possible legal challenges — appears probable. Journalists, compounders, and patients alike will need to await FDA's full publication of the policy to assess its actual scope, consistent with the agency's historical practice of incremental, substance-by-substance rulemaking in this area.